- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03519451
Utilisation d'une application mobile pour smartphone (App) pour améliorer le traitement de sevrage tabagique
Utilisation d'une application mobile pour smartphone (App) pour améliorer le traitement de sevrage tabagique - Une étude pilote
This trial studies how well smartphone mobile applications work in enhancing smoking cessation treatment in current smokers. Smartphone mobile applications may help current smokers quit smoking.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PRIMARY OBJECTIVES:
I. To test the acceptability and preliminary efficacy of a smartphone health application (app), Kick Ash, which will incorporate brief behavioral activation versus (vs.) a relaxation app, Breathe2Relax in a small randomized controlled trial of smokers with elevated depressive symptoms.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I: Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
GROUP II: Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- M D Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- MD Anderson patient between the ages of 18 to 65
- Current smoker (i.e., at least 1 cigarette or e-cigarette per day)
- Smoking for at least one year
- Willing to set a quit date in the next 30 days
- Not engaged in smoking cessation treatment other than the MDACC Tobacco Treatment Program
- Currently elevated depressive symptoms or a history of elevated depressive symptoms; (PHQ 2 = or > 1); current or past
- English speaking and ability to read and comprehend English
- Currently own an iOS mobile phone or tablet (iPhone; iPad) using iOS 9.0 or later and reports regular use (at least weekly) of at least 1 iOS app
Exclusion Criteria:
- Any medical or psychiatric condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator or Collaborator
- Subject considered by the investigator an unsuitable candidate for receipt of a smoking cessation treatment or unstable to be followed up throughout the entire duration of the study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group I (KickAsh smartphone mobile application)
Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks. |
Ancillary studies Given KickAsh smartphone mobile application Given Breathe2Relax smartphone mobile application |
|
Expérimental: Group II (Breathe2Relax smartphone mobile application)
Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks. |
Ancillary studies Given KickAsh smartphone mobile application Given Breathe2Relax smartphone mobile application |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
KickAsh group compliance with mood rating
Délai: Up to 8 weeks from start of study
|
KickAsh group compliance with mood rating determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
|
KickAsh group change in activity level
Délai: Up to 8 weeks from start of study
|
KickAsh group change in activity level determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
|
KickAsh group user satisfaction
Délai: Up to 8 weeks from start of study
|
KickAsh group user satisfaction determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
|
Evidence of increased activity level in KickAsh and Breathe2Relax groups
Délai: Up to 8 weeks from start of study
|
Increase in activity level determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
|
Evidence of improved mood in KickAsh and Breathe2Relax groups
Délai: Up to 8 weeks from start of study
|
Evidence of improved mood determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
|
Evidence of greater smoking abstinence in KickAsh and Breathe2Relax groups
Délai: Up to 8 weeks from start of study
|
Evidence of greater smoking abstinence determined by questionnaires, phone calls, and interview. |
Up to 8 weeks from start of study
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Jennifer A Minnix, M.D. Anderson Cancer Center
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2017-0720
- 2017-0720 (Autre identifiant: M D Anderson Cancer Center)
- NCI-2018-01158 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- R43CA206682 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .